Fidaxomicin: Difimicin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101.

Article Details

Citation
Copy to clipboard

Authors unspecified

Fidaxomicin: Difimicin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101.

Drugs R D. 2010;10(1):37-45. doi: 10.2165/11537730-000000000-00000.

PubMed ID
20509714 [ View in PubMed
]
Abstract

Fidaxomicin, an RNA polymerase inhibitor, is being developed by Optimer and Par Pharmaceuticals as a narrow-spectrum antibacterial for the treatment of Clostridium difficile infections. It is currently in phase III development with promising results so far. This review looks at the development history and scientific profile of this drug to date.

DrugBank Data that Cites this Article

Drugs